SEP
GILD icon

Signature Equity Partners’s Gilead Sciences GILD Stock Holding History

Signature Equity Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.7K Buy
187
+32
+21% +$4.22K 0.01% 609
2026
Q1 		$21.6K Sell
155
-48
-24% -$6.72K 0.01% 618
2025
Q4 		$24.9K Buy
+203
New +$24.7K 0.01% 577

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Signature Equity Partners's GILD Position: Q2 2026 in Review

Signature Equity Partners increased its Gilead Sciences (GILD) stake by 21% in Q2 2026, buying an estimated $4.22K and bringing the position to 187 shares worth $23.7K. The position accounts for 0.01% of the portfolio, ranked #609.

Signature Equity Partners first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $24.9K in Q4 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Signature Equity Partners held 187 shares of Gilead Sciences worth $23.7K as of Q2 2026.
  • Signature Equity Partners bought 32 Gilead Sciences shares in Q2 2026, an estimated $4.22K.
  • Gilead Sciences made up 0.01% of Signature Equity Partners's portfolio in Q2 2026, its #609 holding.
  • Signature Equity Partners first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Signature Equity Partners's Gilead Sciences position peaked at $24.9K in Q4 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.